Olema Pharmaceuticals inc
OLMAHealthcare|Biotechnology|USA
$11.91
-0.38 (-3.09%)
Tangible Book
$5.50
Earnings Power
$4.80
Financials
Financial Snapshot
Market Cap
$1.04B
Enterprise Value
$501.4M
Revenue (TTM)
$0.00
Net Income (TTM)
$-185.2M
Cash & Equivalents
—
Net Cash/Share
$5.21
Free Cash Flow (TTM)
$-148.7M
Operating CF (TTM)
$-148.7M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$37.2M
Monthly Burn
$12.4M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.1M | $68.0K | $338.5M | $287.3M | $204.4M | $261.8M | $434.1M | $505.4M | $505.3M | |
| Operating Cash Flow | $-2.2M | $-3.1M | $-19.9M | $-50.7M | $-82.1M | $-83.7M | $-104.4M | $-146.7M | $-148.7M | |
| Free Cash Flow | $-2.2M | $-3.1M | $-19.9M | $-52.3M | $-82.4M | $-83.7M | $-104.5M | $-146.7M | $-148.7M | |
| Capital Expenditure | $0.00 | $0.00 | $-56.0K | $-1.6M | $-363.0K | $0.00 | $-159.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $5.3M | $0.00 | $358.4M | $1.4M | $476.0K | $133.4M | $268.8M | $211.3M | $256.8M |
R&D Spending
R&D (TTM)
$176.3M
R&D Intensity
—
R&D Growth YoY
+11.8%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.7M | $3.9M | $13.7M | $51.1M | $82.3M | $86.1M | $124.5M | $157.7M | $176.3M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | |
| SG&A | $386.0K | $403.0K | $7.8M | $20.4M | $24.7M | $18.8M | $17.7M | $21.0M | $25.5M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $1.7M | $3.9M | $13.7M | $51.1M | $82.3M | $86.1M | $124.5M | $157.7M | $176.3M | |
| SG&A | $386.0K | $403.0K | $7.8M | $20.4M | $24.7M | $18.8M | $17.7M | $21.0M | $25.5M | |
| Operating Income | $-2.1M | $-4.3M | $-21.5M | $-71.5M | $-107.0M | $-105.0M | $-142.3M | $-178.7M | $-201.8M | |
| Interest Expense | $-28.0K | $0.00 | $-653.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-2.2M | $-4.3M | $-22.1M | $-71.1M | $-104.8M | $-96.7M | $-129.5M | $-162.5M | $-185.2M | |
| Net Income | $-2.2M | $-4.3M | $-22.1M | $-71.1M | $-104.8M | $-96.7M | $-129.5M | $-162.5M | $-185.2M | |
| EPS (Diluted) | -0.16 | -0.31 | -3.42 | -1.80 | -2.62 | -2.14 | -2.20 | -1.87 | -2.03 | |
| EBITDA | $-2.2M | $-4.3M | $-21.5M | $-71.3M | $-106.6M | $-104.6M | $-141.9M | $-178.2M | $-201.3M | |
| Shares Out. (M) | 14.10 | 14.10 | 7.02 | 39.52 | 39.99 | 45.25 | 58.74 | 87.01 | 102.80 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $68.0K | $338.5M | $13.8M | $23.7M | $68.5M | $139.5M | $48.3M | $52.5M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $273.4M | $180.7M | $193.3M | $294.6M | $457.1M | $452.8M | |
| Total Current Assets | $3.2M | $103.0K | $342.1M | $290.7M | $208.9M | $266.5M | $438.5M | $515.5M | $513.2M | |
| Total Assets | $3.3M | $132.0K | $342.7M | $295.9M | $215.6M | $276.9M | $451.0M | $533.4M | $530.6M | |
| Total Current Liabilities | $201.0K | $1.4M | $4.6M | $9.0M | $16.5M | $21.6M | $41.8M | $51.8M | $47.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.0M | $3.0M | |
| Total Liabilities | $9.5M | $10.7M | $4.6M | $11.4M | $18.1M | $23.1M | $42.0M | $54.9M | $50.2M | |
| Stockholders' Equity | $-6.3M | $-10.6M | $338.1M | $284.6M | $197.5M | $253.9M | $409.0M | $478.6M | $480.5M | |
| Retained Earnings | $-6.4M | $-10.8M | $-33.1M | $-104.2M | $-209.0M | $-305.6M | $-435.1M | $-597.6M | $-650.6M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-2.2M | $-3.1M | $-19.9M | $-50.7M | $-82.1M | $-83.7M | $-104.4M | $-146.7M | $-148.7M | |
| Capital Expenditure | $0.00 | $0.00 | $-56.0K | $-1.6M | $-363.0K | $0.00 | $-159.0K | $0.00 | $0.00 | |
| Free Cash Flow | $-2.2M | $-3.1M | $-19.9M | $-52.3M | $-82.4M | $-83.7M | $-104.5M | $-146.7M | $-148.7M | |
| Investing Cash Flow | $0.00 | $0.00 | $-56.0K | $-275.4M | $91.5M | $-4.9M | $-93.5M | $-155.8M | $-106.1M | |
| Financing Cash Flow | $5.3M | $0.00 | $358.4M | $1.4M | $476.0K | $133.4M | $268.8M | $211.3M | $256.8M | |
| Issuance of Stock | $0.00 | $0.00 | $220.6M | $0.00 | $0.00 | $129.7M | $266.3M | $205.4M | $247.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $323.0K | $0.00 | $3.1M | $0.00 | $0.00 | $0.00 | $0.00 | $3.0M | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.0K | $0.00 | $3.1M | $15.9M | $18.8M | $17.3M | $22.6M | $17.6M | $23.4M | |
| Net Change in Cash | $3.1M | $-3.1M | $338.5M | $-324.7M | $9.9M | $44.8M | $70.9M | $-91.2M | $1.9M |
Dilution Tracker
Shares outstanding grew 160.1% over 5 years — significant dilution
Shares Outstanding
103M
5-Year Share Growth
+160.1%
Stock Issuance (TTM)
$247.3M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 14.10 | 14.10 | 7.02 | 39.52 | 39.99 | 45.25 | 58.74 | 87.01 | 102.80 | |
| YoY Change % | — | 0.0% | -50.2% | 462.9% | 1.2% | 13.1% | 29.8% | 48.1% | 18.2% | |
| Stock Issuance | $0.00 | $0.00 | $220.6M | $0.00 | $0.00 | $129.7M | $266.3M | $205.4M | $247.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.0K | $0.00 | $3.1M | $15.9M | $18.8M | $17.3M | $22.6M | $17.6M | $23.4M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | -13.5% | -22.8% | -43.5% | -42.8% | -39.1% | -36.6% | -46.4% | |
| ROA % | -67.2% | -253.7% | -12.9% | -22.3% | -41.0% | -39.2% | -35.6% | -33.0% | -41.9% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B2.17
Historical— / — / 2.17
Industry Med.2.93
EV/EBITDA-2.68
Historical-2.68 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$5.50
Net Current Assets
$5.300
Net-Net Working Capital
$5.21
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 5.59 | 1.31 | 0.50 | 3.04 | 1.06 | 4.25 | 2.17 | |
| EV/EBITDA | 0.00 | 0.00 | -72.30 | -1.24 | 0.97 | -4.90 | 0.00 | -8.60 | -2.68 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $23.09M | $121.76M |
| Net Income | $-225.45M | $-258.16M | $-222.71M |
| EPS | -2.24 | -2.53 | -2.20 |
| Book Value per Share | 3.92 | 2.58 | 2.26 |
| Operating Cash Flow per Share | -1.97 | -2.14 | -1.83 |
| Operating CF | $-202.52M | $-219.48M | $-188.12M |